Retinitis pigmentosa-linked mutation in DHX38 modulates its splicing activity

PLoS One. 2022 Apr 6;17(4):e0265742. doi: 10.1371/journal.pone.0265742. eCollection 2022.

Abstract

Retinitis pigmentosa (RP) is a hereditary disease affecting tens of thousands of people world-wide. Here we analyzed the effect of an amino acid substitution in the RNA helicase DHX38 (Prp16) causing RP. DHX38 has been proposed as the helicase important for the 2nd step of splicing. We showed that DHX38 associates with key splicing factors involved in both splicing steps but did not find any evidence that the RP mutations changes DHX38 interaction profile with the spliceosome. We further downregulated DHX38 and monitored changes in splicing. We observed only minor perturbations of general splicing but detected modulation of ~70 alternative splicing events. Next, we probed DHX38 function in splicing of retina specific genes and found that FSCN2 splicing is dependent on DHX38. In addition, RHO splicing was inhibited specifically by expression of DHX38 RP variant. Finally, we showed that overexpression of DHX38 promotes usage of canonical as well as cryptic 5' splice sites in HBB splicing reporter. Together, our data show that DHX38 is a splicing factor that promotes splicing of cryptic splice sites and regulate alternative splicing. We further provide evidence that the RP-linked substitution G332D modulates DHX38 splicing activity.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • DEAD-box RNA Helicases* / genetics
  • Humans
  • Mutation
  • RNA Splice Sites
  • RNA Splicing
  • RNA Splicing Factors* / genetics
  • Retinitis Pigmentosa* / genetics
  • Spliceosomes / metabolism

Substances

  • RNA Splice Sites
  • RNA Splicing Factors
  • DHX38 protein, human
  • DEAD-box RNA Helicases

Grants and funding

This work was supported by the Czech Academy of Sciences (RVO68378050 and RVO68378050-KAV-NPUI), the Czech Science Foundation 18-01911J (to Z.C.), the Ministry of Education, Youth and Sports CZ.02.1.01/0.0/0.0/16_019/0000785 (to M.K) and the Charles University Grant Agency 1270217 (to M.O.). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.